AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
ASPX was delisted on the 4th of May, 2015.
71 hedge funds and large institutions have $310M invested in AUSPEX PHARMACEUTICALS INC COM STK (DE) in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 9 reducing their positions, and 9 closing their positions.
278% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 9
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
56% more capital invested
Capital invested by funds: $198M → $310M (+$112M)
16% more funds holding
Funds holding: 61 → 71 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$11.2M |
| 2 |
Millennium Management
New York
|
+$10.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.53M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.67M |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.04M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.05M |
| 3 |
Morgan Stanley
New York
|
-$836K |
| 4 |
Jennison Associates
New York
|
-$425K |
| 5 |
PP
PDT Partners
New York
|
-$399K |
ASPX Hedge Fund Activity: Q3 2014 in Review
71 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) for Q3 2014, worth a combined $310M — up 56% from $198M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ASPX positions and 9 closed out — a net gain of 10 holders — while 34 added to existing stakes and 9 trimmed.
The largest buyer was Deerfield Management, adding an estimated $11.2M. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.04M sold.
- 71 institutional investors held AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) as of Q3 2014, up from 61 in Q2 2014.
- Funds reported $310M of AUSPEX PHARMACEUTICALS INC COM STK (DE) stock for Q3 2014, up 56% quarter-over-quarter.
- 19 funds opened new AUSPEX PHARMACEUTICALS INC COM STK (DE) positions in Q3 2014 and 9 closed out, a net change of +10 holders.
- The largest AUSPEX PHARMACEUTICALS INC COM STK (DE) buyer in Q3 2014 was Deerfield Management, an estimated $11.2M added.
- The largest AUSPEX PHARMACEUTICALS INC COM STK (DE) seller in Q3 2014 was Wellington Management Group, an estimated $2.04M sold.
Based on aggregated 13F filings for Q3 2014.